Pfizer to acquire Reviral as RSV race continues

The proposed USD 525m acquisition includes therapeutic candidates within the RSV indication, which Bavarian Nordic is also targeting.
Photo: CARLO ALLEGRI/REUTERS / X90181
Photo: CARLO ALLEGRI/REUTERS / X90181

Pharmaceutical giant Pfizer is continuing to expand its efforts within the RSV indication, fresh off success with its Covid-19 vaccine.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading